These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 39050747)

  • 1. The real-world safety of oseltamivir and baloxavir marboxil in children: a disproportionality analysis of the FDA adverse event reporting system.
    Wei W; Huang L; Bai Y; Chang E; Liu J
    Front Pharmacol; 2024; 15():1391003. PubMed ID: 39050747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety analysis of Oseltamivir and Baloxavir Marboxil after market approval: a pharmacovigilance study based on the FDA adverse event reporting system.
    Li Y; Wang X; Liao Y; Zeng Y; Lin W; Zhuang W
    BMC Infect Dis; 2024 May; 24(1):446. PubMed ID: 38724914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A real-world disproportionality analysis of baloxavir marboxil: post-marketing pharmacovigilance data.
    Zhou J; Ye J; Chen M; Zheng X
    Expert Opin Drug Saf; 2024 Sep; ():1-9. PubMed ID: 39234783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suspected adverse drug reactions of rivaroxaban reported in the United States food and drug administration adverse event reporting system database: a pharmacovigilance study.
    Wu J; Wu J; Tang B; Wang X; Wei F; Zhang Y; Li L; Li H; Wang B; Wu W; Hong X
    Front Pharmacol; 2024; 15():1399172. PubMed ID: 39309013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System.
    Shu Y; Ding Y; Liu Y; Wu P; He X; Zhang Q
    Front Pharmacol; 2022; 13():862508. PubMed ID: 35754494
    [No Abstract]   [Full Text] [Related]  

  • 6. A real-world pharmacovigilance analysis of eslicarbazepine acetate using the FDA adverse events reporting system (FAERS) database from 2013 (Q4) to 2024 (Q1).
    Tang H; Xu J; Zhang X; Chen C; Song G; Ma R; Zhao J; Zhao Q
    Front Pharmacol; 2024; 15():1463560. PubMed ID: 39372199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse event reporting of the IGF-1R monoclonal antibody teprotumumab: a real-world study based on the US food and drug administration adverse event reporting system.
    Zhao J; Tao Y
    Front Pharmacol; 2024; 15():1393940. PubMed ID: 39185318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety assessment of Tafamidis: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events.
    Li Y; Sun S; Wu H; Zhao L; Peng W
    BMC Pharmacol Toxicol; 2024 Sep; 25(1):71. PubMed ID: 39334280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A real-world pharmacovigilance study of abaloparatide based on the FDA Adverse Event Reporting System (FAERS).
    Shi X; Cheng Q; Zhao YZ; Zou SP; Sun MH
    Osteoporos Int; 2023 Dec; 34(12):2047-2058. PubMed ID: 37594595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse events associated with eteplirsen: A disproportionality analysis using the 2016-2023 FAERS data.
    Dai Z; Wang G; Zhang J; Zhao Q; Jiang L
    Heliyon; 2024 Jul; 10(13):e33417. PubMed ID: 39027557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-marketing drug safety surveillance of enfortumab vedotin: an observational pharmacovigilance study based on a real-world database.
    Yu M; Zhou L; Cao M; Ji C; Zheng Y
    Front Immunol; 2024; 15():1397692. PubMed ID: 39234238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-marketing safety concerns with abrocitinib: a real-world pharmacovigilance analysis of the FDA adverse event reporting system.
    Zhu Z; Liu M; Zhang H; Zheng H; Li J
    Expert Opin Drug Saf; 2024 May; ():1-8. PubMed ID: 38743462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-Marketing Safety Concerns with Upadacitinib: A Disproportionality Analysis of the FDA Adverse Event Reporting system.
    Wu XP; Lu XK; Wang ZT; Huang L; Cai RW; Yu HM; Li JY; Xiao J
    Expert Opin Drug Saf; 2023; 22(10):975-984. PubMed ID: 37310063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral influenza treatments and hemorrhage-related adverse events in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database.
    Sarker J; Carkovic E; Ptaszek K; Lee TA
    Pharmacotherapy; 2024 May; 44(5):383-393. PubMed ID: 38656741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A real-world disproportionality analysis of sacubitril/valsartan: data mining of the FDA adverse event reporting system.
    Wang Y; Liu X
    Front Pharmacol; 2024; 15():1392263. PubMed ID: 39193332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system.
    Shu Y; Ding Y; Dai B; Zhang Q
    Expert Opin Drug Saf; 2022 Apr; 21(4):563-572. PubMed ID: 34918584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-marketing safety concerns with relugolix: a disproportionality analysis of the FDA adverse event reporting system.
    Xia C; Liu Z; Liu J; Lin L; Chen M
    Invest New Drugs; 2024 Aug; ():. PubMed ID: 39133357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world effectiveness and safety of Baloxavir Marboxil or Oseltamivir in outpatients with uncomplicated influenza A: an ambispective, observational, multi-center study.
    Cai J; Wang H; Ye X; Lu S; Tan Z; Li Z; Lin D; Qian J; Lu X; Wan J; Wang J; Ai J; Pu Y; Qu L; Wang S
    Front Microbiol; 2024; 15():1428095. PubMed ID: 39109213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-marketing safety concerns with elagolix: a disproportionality analysis of the FDA adverse event reporting system.
    Chang E; Shi YF; Liu JF; Wei W
    Expert Opin Drug Saf; 2024 May; ():1-8. PubMed ID: 38700323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-marketing safety evaluation of lurbinectedin: a pharmacovigilance analysis based on the FAERS database.
    Li Z; Guo C; Liu X; Qiu Z; Zhang R
    Front Pharmacol; 2024; 15():1368763. PubMed ID: 38549677
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.